IADSA on health claims
This article was originally published in The Tan Sheet
Executive Summary
Relying solely on human intervention studies to substantiate health claims is impractical and the Codex Alimentarius recommendations for the scientific basis of health claims should take into account the totality of evidence, the International Alliance of Dietary/Food Supplement Associations says. The draft of the recommendations states human trials are the prime source of evidence to back health claims and "makes no reference to evidence based on traditional knowledge and history of use," IADSA says. While human trials are important, they are only one source of information and "all sources of scientific data have inherent limitations, hence the need to focus on the totality of the available data and weighing of the evidence," says David Richardson, scientific adviser to the U.K. Council for Responsible Nutrition and IADSA. CRN and other members of the supplement and nutrition industry have long protested the pharmaceutical model of testing nutrients (1"The Tan Sheet" May 7, 2007, p. 12)...
You may also be interested in...
Supplement Firms Should Value RCTs, But Also Improve Other Research – CRN
Supplement firms must adapt clinical research methods to accommodate the industry's unique challenges and gain acceptance from mainstream medicine, Council for Responsible Nutrition President and CEO Steve Mister said during the trade group's Day of Science workshop May 3
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.